Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.96 |
| ▸ | PGR | P06401 | 3/20 | 0.96 |
| ▸ | TSHR | P16473 | 2/20 | 0.96 |
| ▸ | AR | P10275 | 2/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.96 |
| ▸ | MEN1 | O00255 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.96 |
| ▸ | APEX1 | P27695 | 1/20 | 0.96 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.96 |
| ▸ | IKBKB | O14920 | 1/20 | 0.96 |
| ▸ | CHUK | O15111 | 1/20 | 0.96 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.96 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.96 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.96 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL5032605 | 0.99 | HIF1A (0.95) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL12673028 | 0.98 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL13615614 | 0.98 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL10600952 | 0.98 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL23022353 | 0.98 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL24556970 | 0.98 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21790369 | 0.98 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL20816248 | 0.98 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21261932 | 0.98 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL13479432 | 0.98 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274681-B2 | Compositions and methods for reducing skin fat | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | claimed |
| CN-119770420-A | Application of multifunctional manganese-based hydrogel in regulating energy metabolism and promoting bone regeneration | 苏州大学附属第一医院 | 2025-04-08 | — | — | CN | claimed |
| CN-118304475-A | Preparation method of pH-responsive polydopamine coating-loaded dexamethasone and BMP-2 mesoporous silicon nanometer osteogenesis system | 青岛大学附属医院 | 2024-07-09 | — | — | CN | claimed |
| WO-2023182540-A1 | COMPOSITION FOR PREVENTING AND AMELIORATING VIRAL DISEASE | 주식회사 벤스랩 | 2023-09-28 | — | — | WO | claimed |
| US-20230270701-A1 | COMPOSITIONS AND METHODS FOR REDUCING SKIN FAT | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | claimed |
| CN-116459357-A | Fullerol-eutectic solvent-agarose composite gel for electrically-driven drug release | 四川大学 | 2023-07-21 | — | — | CN | claimed |
| CN-115671260-A | Pharmaceutical composition, culture medium and method for inducing adipogenic differentiation of tumor cells | 湖南中医药大学 | 2023-02-03 | — | — | CN | claimed |
| EP-3777536-A1 | POVIDONE IODINE, A NOVEL ALTERNATIVE PRESERVATIVE FOR OPHTHALMIC COMPOSITIONS | Takeda Pharmaceutical Company Limited (JP) | 2021-02-17 | — | — | EP | claimed |
| CN-101400355-B | Ophthalmic compositions comprising povidone-iodine | 科莱鲁CLS控股公司 | 2018-07-24 | — | — | CN | claimed |
| EP-3288589-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | Foresight Biotherapeutics, Inc. (US) | 2018-03-07 | — | — | EP | claimed |
| US-20030139382-A1 | Mixture of dexamethasone and ciprofloxacin | ALCON, INC. | 2003-07-24 | — | — | US | claimed |
| WO-2003026671-A1 | METHOD OF TREATING MIDDLE EAR INFECTIONS | ALCON, INC. (CH) | 2003-04-03 | — | — | WO | claimed |
| CN-1376054-A | Topcial suspension formulations containing ciprofloxacin and dexa methasone | ALCON LTD (CH) | 2002-10-23 | — | — | CN | claimed |
| EP-1214056-A1 | TOPICAL SUSPENSION FORMULATIONS CONTAINING CIPROFLOXACIN AND DEXAMETHASONE | Alcon Universal, Ltd. (CH) | 2002-06-19 | — | — | EP | claimed |
| US-6359016-B2 | FOR EYES, EARS OR NOSES | ALCON UNIVERSAL LTD. (CH) | 2002-03-19 | — | — | US | claimed |
| US-20010049366-A1 | Topical solution formulations containing an antibiotic and a corticosteroid | ALCON UNIVERSAL LTD. | 2001-12-06 | — | — | US | claimed |
| US-20010034339-A1 | Topical suspension formulations containing ciprofloxacin and dexamethasone | NOVARTIS AG (CH) | 2001-10-25 | — | — | US | claimed |
| US-6284804-B1 | INTENDED FOR APPLICATION TO THE EYE, EAR OR NOSE | ALCON UNIVERSAL LTD. (CH) | 2001-09-04 | — | — | US | claimed |
| WO-2001022936-A1 | TOPICAL SUSPENSION FORMULATIONS CONTAINING CIPROFLOXACIN AND DEXAMETHASONE | ALCON UNIVERSAL LTD. (CH) | 2001-04-05 | — | — | WO | claimed |
| US-5698533-A | Ophthalmic pharmaceutical composition | KANG MENG-CHE (TW) | 1997-12-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274681-B2 | Compositions and methods for reducing skin fat | ACAT1, ACAT2, ACACA | NR3C1 1078/4885HIF1A 3174/4885CYP3A4 1885/4885 |
| US-20230270701-A1 | COMPOSITIONS AND METHODS FOR REDUCING SKIN FAT | ACAT1, ACAT2, ACACA | NR3C1 1078/4885HIF1A 3174/4885CYP3A4 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.